WALTHAM, Mass., May 12, 2020 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical-stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced the
closing of its previously announced underwritten public offering of
6,388,889 shares of its common stock at a price to the public of
$18.00 per share. This includes the
exercise in full by the underwriters of their option to purchase up
to 833,333 additional shares of common stock. The aggregate gross
proceeds to Syndax from this offering were approximately
$115 million, before deducting
underwriting discounts and commissions and estimated offering
expenses payable by Syndax.
Citigroup and Cowen acted as joint book-running managers for the
offering. Barclays acted as joint bookrunning manager. BTIG acted
as lead manager, and Baird acted as co-manager.
The shares were offered pursuant to a "shelf" registration
statement previously filed and declared effective by the Securities
and Exchange Commission (SEC). A final prospectus supplement and
accompanying prospectus relating to the offering were filed with
the SEC and are available on the SEC's website located at
http://www.sec.gov. Copies of the final prospectus supplement and
accompanying prospectus relating to the offering may be obtained
from: Citigroup Global Markets Inc., c/o Broadridge Financial
Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at (800)
831-9146; or Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at
PostSaleManualRequests@broadridge.com, or by phone at (833)
297-2926.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. The Company's lead product candidate, entinostat,
a once-weekly, oral, small molecule, class I HDAC inhibitor, is
being tested in a Phase 3 combination trial with exemestane for
treatment of advanced HR+, HER2- breast cancer and has been
evaluated in combination with several approved PD-1/PD-(L)1
antagonists. The Company's pipeline also includes axatilimab
(SNDX-6352), a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor, and SNDX-5613, a highly
selective inhibitor of the menin–MLL binding interaction.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Factors that may cause Syndax's actual results to
differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Syndax's filings
with the U.S. Securities and Exchange Commission, including
the "Risk Factors" sections contained therein, as well as the risks
identified in the registration statement and the preliminary
prospectus supplement relating to the offering. These
forward-looking statements are based on Syndax's expectations and
assumptions as of the date of this press release. Except as
required by law, Syndax assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301057848.html
SOURCE Syndax Pharmaceuticals, Inc.